scholarly journals Intestinal obstruction due to primary ileocolic diffuse large B-cell lymphoma: A case report

2021 ◽  
Vol 2 (3) ◽  
Author(s):  
Marina Alarcón Iranzo ◽  
◽  
Matías Gómez Calomarde ◽  
Estefanía Zorraquino ◽  
Miguel Ángel Sanz ◽  
...  
Keyword(s):  
Intestinal Obstruction ◽  
B Cell ◽  
Cell Lymphoma ◽  
Ileocecal Valve ◽  
B Cell Lymphoma ◽  
Presenting Symptoms ◽  
Large B Cell Lymphoma ◽  
Frequent Site ◽  
Surgery Management ◽  
Large B Cell

The Gastrointestinal (GI) tract is the most frequent site of extranodal lymphoma involvement. Most GI lymphomas are non-Hodgkin’s mature B-cell lymphomas, being diffuse large B-cell lymphoma one of the most common histologic subtypes. About 7% of GI lymphomas are located in the colon, usually at the ileocecal valve, and may grow into the terminal ileum. Abdominal pain and weight loss are common presenting symptoms, although complications such as intestinal obstruction may occur. Abdominal CT scan and barium enema are the most frequently used imaging tests for diagnosis, although colonoscopy with biopsies is required to confirm the diagnosis. Treatment includes surgery and chemotherapy with or without rituximab. Keywords: Primary colonic lymphoma; Diffuse large B-Cell Lymphoma; Obstruction; Surgery; Management.

scholarly journals Severe peripheral oedema as the only presenting symptom of intravascular large B-cell lymphoma: a diagnosis too frequently made on autopsy

2019 ◽  
Vol 12 (5) ◽  
pp. e228802
Author(s):  
Rachel Kyle ◽  
Gillian Mount ◽  
Shao Shi Li ◽  
Jenny Thain
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Multiorgan Failure ◽  
B Cell Lymphoma ◽  
Definitive Diagnosis ◽  
Peripheral Oedema ◽  
Presenting Symptoms ◽  
Predominant Symptom ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Intravascular large B-cell lymphoma is seen in less than one per million people and can be an extremely difficult antemortem diagnosis to make due to a vast diversity of presenting symptoms. We present a case of an otherwise healthy 74-year-old woman whose predominant symptom was pitting oedema, and who likely died from multiorgan failure after >14 months of extensive workup that was unable to secure a definitive diagnosis.

scholarly journals Intestinal lymphangiectasia: a rare cause of intussusception in an adolescent

2019 ◽  
Vol 101 (2) ◽  
pp. e43-e44
Author(s):  
S Kumar ◽  
K Raja ◽  
S Gnanasekaran ◽  
B Pottakkat
Keyword(s):  
Case Report ◽  
Intestinal Obstruction ◽  
B Cell ◽  
Induction Chemotherapy ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Intestinal Lymphangiectasia ◽  
Lead Point ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Intussusception in adolescents is usually idiopathic in nature. A 17-year-old woman with diffuse large B cell lymphoma presented with signs of intestinal obstruction after initiation of induction chemotherapy. On evaluation, the patient was diagnosed to have ileoileal intussusception with intestinal lymphangiectasia as the lead point. Intestinal lymphangiectasia as a rare cause for intussusception and its relationship with lymphoma is discussed in this case report.

Lymphome

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Staging System ◽  
Maligne Lymphome ◽  
Interim Pet ◽  
Large B Cell Lymphoma ◽  
Ann Arbor ◽  
Large B Cell

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.

Sign in / Sign up

Export Citation Format

Share Document